At this burn, runway ends — and what the runway is buying is usually one or two clinical assets, defined by their IP. Kodiak Sciences holds US12643958B2, "Methods of treating an eye disorder" (issued June 2, 2026), a grant whose CPC tags — C07K 17/08 (immobilized antibodies), A61K 47/605/47/6845 (conjugates), A61P 27/02 (ophthalmic) — point to a conjugated anti-VEGF-class approach to retinal disease, the same therapeutic territory as the franchise blockbusters.
Here is the dilution-math context. A single-asset or narrow-pipeline retinal company spends heavily on long, expensive ophthalmology trials, and it funds that spend by issuing equity — secondaries, ATMs, sometimes convertibles. Each raise buys quarters, not years, and dilutes existing holders. The issued grant is the asset that justifies the raise; the burn rate is what determines whether the company reaches its next value-inflecting readout before the cash runs out.
What an investor-protective read demands: gross proceeds are not net, and a headline raise size is not runway. Runway is cash plus net proceeds divided by quarterly burn — and for a trial-stage ophthalmology asset, burn is high and lumpy around trial milestones. The grant tells you the company owns something specific worth financing; it tells you nothing about how many more financings it will take to monetize it.
What the patent does not address: trial outcomes, the crowded anti-VEGF competitive field, or the warrant overhang and share-count impact of the financings that keep the lights on. A grant on an eye-disorder method is an exclusivity claim on a specific approach; the dilution and runway risks live entirely in the balance sheet and the financing documents, not in the patent.
The capital-markets takeaway: when a retinal-disease small-cap raises money, the issued IP — like this Kodiak grant — tells you what the capital is buying, but the burn rate and the dilution tell you whether holders get to the payoff. Read the asset and the balance sheet together; financing a strong patent at a brutal burn is still a race against the cash.